Side-by-side · Research reference

KPVvsVilon

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-StrongAUTO-DRAFTED13/39 cited

BAnimal-StrongHUMAN-REVIEWED13/49 cited

KPV

α-MSH C-terminal · Anti-inflammatory

200–500 mcgDaily doseDalle-Pang 2024

AnimalEvidence levelDalle-Pang 2024

HoursHalf-life (est)

SQ / oral / topical · Local · Daily or 2-3×/week

Vilon

Khavinson Bioregulator · Dipeptide

2 AADipeptide

T-helperStimulatesLinkova 2011

MouseModel basisKhavinson 2002

Literature lacks standardised clinical route

01Mechanism of Action

Parameter

KPV

Vilon

Primary target

Intracellular targets bypassing melanocortin receptors (proposed)Dalle-Pang 2024

Immune cell differentiation pathways, chromatin modification

Pathway

NF-κB inhibition + cytokine modulation (TNF-α, IL-1β, IL-6) → reduced inflammationDalle-Pang 2024

Vilon → Thymocyte sphingomyelinase activation → T-helper & cytotoxic T-cell differentiation; epigenetic suppression of aging markers (CCL11, HMGB1)

Downstream effect

Anti-inflammatory action without α-MSH pigmentation effects; gut barrier protectionDalle-Pang 2024

Enhanced T-cell differentiation (CD4+, CD8+, B-cells), thymocyte proliferation, modulated IL-1β comitogenic activity, proposed chromatin decondensation in aged lymphocytesLinkova 2011 Khavinson 2002 Lezhava 2023

Feedback intact?

No melanocortin receptor binding

Unknown — no HPA/HPG axis data

Origin

Synthetic tripeptide; the C-terminal Lys-Pro-Val residues of α-MSH (residues 11-13)Dalle-Pang 2024

Synthetic dipeptide derived from Khavinson thymic peptide extraction studies (Thymalin fraction)Morozov 1997

Antibody development

—

02Dosage Protocols

Parameter

KPV

Vilon

Standard dose

200–500 mcg / day SQ or oralDalle-Pang 2024

No clinical standard — literature lacks human dosing

Russian practice: often combined with other Khavinson peptides; no FDA/EMA trials.

Frequency

Daily or 2–3× per week

Unknown — literature does not specify chronic administration protocols

Lower / starter dose

100 mcg / day

—

Evidence basis

Animal-strong + emerging clinical data in IBDDalle-Pang 2024

Mouse / in vitro only

Duration

4–8 weeks per cycle

Not characterised in humans

Reconstitution

Bacteriostatic water (SQ form)

—

Timing

No specific time; often taken with / before meals (oral)

—

Half-life

Hours (estimated; rapid tissue uptake)

Not published — dipeptides typically <10 min plasma t½

Animal model dose

—

In vitro: 0.01–10 μg/mL culture medium (mouse thymocytes)

Not translatable to human mg/kg without pharmacokinetic data.

Route

—

Likely SQ or oral (Khavinson school uses both); no published ROA validation

04Side Effects & Safety

Parameter

KPV

Vilon

Injection site reaction

Mild irritation

—

GI symptoms

Rare nausea (oral form)

—

Pigmentation

None (unlike full α-MSH)Dalle-Pang 2024

—

Long-term safety

Limited human data

—

Pregnancy / OB

Avoid — insufficient data

—

Human safety data

—

Absent from PubMed-indexed literature

Theoretical risk

—

Immune hyperactivation in autoimmune-prone individuals (T-cell differentiation enhancement)

Antibody formation

—

Not reported; dipeptides generally low immunogenicity

Animal models

—

No adverse effects noted in mouse thymocyte or pineal lymphoid cultures

Absolute Contraindications

KPV

·Pregnancy / breastfeeding

Vilon

·Active autoimmune disease (theoretical — no clinical data)

Relative Contraindications

KPV

·Active autoimmune disease (theoretical)

Vilon

·Pregnancy / lactation (no safety data)
·Acute infection with cytokine storm risk (immune modulation unknown)

05Administration Protocol

Parameter

KPV

Vilon

1. Reconstitution

Add 1 mL bacteriostatic water to vial per labelling.

No clinical protocols exist in Western peer-reviewed literature. Russian gerontological practice may use 1–10 mg ranges, but dosing is empirical.

2. Form

SQ injection (acute), oral capsule (chronic / gut), topical for skin indications.

Subcutaneous injection (common for Khavinson peptides) or oral (some bioregulators reportedly active orally due to small size). No validated ROA.

3. Timing

Morning preferred; oral form taken with / before meals.

Unknown — no circadian or meal-timing data. Khavinson school often recommends morning administration.

4. Storage

Lyophilised: room temp, light-protected. Reconstituted: refrigerate ≤30 days.

Likely lyophilised powder, refrigerated. Reconstitution protocols not published.

5. Needle

29–31G insulin syringe (SQ form).

—

06Stack Synergy

KPV

+ BPC-157

Strong

View BPC-157 →

KPV (NF-κB inhibition, cytokine reduction) + BPC-157 (VEGF-driven angiogenesis, tissue regeneration) form the classic gut-healing stack. KPV reduces inflammatory drive; BPC-157 promotes mucosal repair. Anecdotally favoured for IBD, ulcerative colitis, and post-surgical gut recovery.

KPV: 200–500 mcg oral · daily
BPC-157: 250–500 mcg oral or SQ · daily
Primary benefit: Combined anti-inflammation + mucosal repair for gut conditions

Dalle-Pang 2024 Sikiric 2018

Vilon

+ Epitalon

Moderate

View Epitalon →

Both are Khavinson bioregulators targeting aging pathways. Epitalon (Ala-Glu-Asp-Gly) acts on telomerase and pineal function; Vilon on immune differentiation and chromatin decondensation. Combined in Russian gerontological protocols for multi-system aging intervention. Lezhava et al. (2023) tested both on aged lymphocyte chromatin, showing distinct epigenetic effects. Complementary, not synergistic in strict pharmacological sense.

Vilon: Empirical — no standard
Epitalon: Empirical — often 10 mg cycles
Frequency: Sequential or concurrent (literature ambiguous)
Primary benefit: Multi-system aging modulation (immune + pineal/circadian)

+ Thymalin

Weak

View Thymalin →

Thymalin is the parent polypeptide complex from which Vilon was isolated. Both target immune differentiation, but Thymalin is a complex mixture (multiple peptides), whereas Vilon is a purified dipeptide. Morozov & Khavinson (1997) described Vilon as a synthetic successor designed to replicate Thymalin's immunomodulatory effects with greater specificity. Redundant in practice; no published combination studies.

Vilon: No standard
Thymalin: 10–100 mg IM (polypeptide complex)
Primary benefit: Redundant — both target T-cell differentiation

Morozov 1997 Khavinson 2020